Results 191 to 200 of about 7,648 (236)

Momelotinib for myelofibrosis. [PDF]

Aust Prescr
europepmc   +1 more source

Discoidin domain receptor 2 is an important modulator of BMP signaling during heterotopic bone formation. [PDF]

Bone Res
Wu F, Ge C, Pan H, Han Y, Mishina Y, Kaartinen V, Franceschi RT.   +6 more
europepmc   +1 more source

CD9-enriched extracellular vesicles from chemically reprogrammed basal progenitors of salivary glands mitigate salivary gland fibrosis. [PDF]

Bioact Mater
Park S, Yoon YJ, Hong Y, Yu J, Cho JM, Jeong YJ, Yu H, Jeong H, Lee H, Hwang S, Koh WG, Yang JY, Hyun KA, Jung HI, Lim JY.   +14 more
europepmc   +1 more source

The role of miRNAs as biomarkers in heterotopic ossification. [PDF]

EFORT Open Rev
Xie C, Liu X, Li W, Yao Z, Men H, Li Z.
europepmc   +1 more source

Connections Between Gene Polymorphism and Fetlock and Hock Measurements in Polish Sport Horses. [PDF]

Int J Mol Sci
Lewczuk D, Wypchło M, Hecold M, Buczkowska R, Korwin-Kossakowska A.   +4 more
europepmc   +1 more source

FDA greenlights momelotinib (Ojjaara) as the exclusive treatment for myelofibrosis patients battling anemia. [PDF]

Ann Med Surg (Lond)
Jehanzeb M, Iqbal U, Farhat N, Waseem R, Shahzad M, Mahmmoud Fadelallah Eljack M.   +5 more
europepmc   +1 more source

When Bone Forms Where It Shouldn't: Heterotopic Ossification in Muscle Injury and Disease. [PDF]

Int J Mol Sci
Facchin A, Lemaire S, Toner LG, Argaw A, Frenette J.   +4 more
europepmc   +1 more source

Managing Myelofibrosis: Matching Advances in Treatments With Clinical Unmet Needs. [PDF]

Hematol Oncol
Wei CT, Than H, Huang FJ, Billa G, Lee LH.   +4 more
europepmc   +1 more source

Macrophage Polarization in Heterotopic Ossification: Inflammation, Osteogenesis, and Emerging Therapeutic Targets. [PDF]

Int J Mol Sci
Ren Y, Zhao W, Liu M, Lin H.
europepmc   +1 more source

Fibroblasts in heterotopic ossification: mechanisms and therapeutic targets. [PDF]

Int J Biol Sci
Li JX, Dang YM, Liu MC, Gao LQ, Lin H.
europepmc   +1 more source